查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933329

全球介入性肿瘤市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考虑因素以及未来预测（2026-2034）

Interventional Oncology Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 120 Pages | 商品交期: 请询问到货日

价格

介入性肿瘤市场成长因素

由于全球癌症负担日益加重以及对微创癌症治疗的需求不断增长，全球介入肿瘤市场正经历稳定成长。预计到2025年，全球介入性肿瘤市场规模将达23.4亿美元。 预计该市场将从2026年的25.3亿美元成长到2034年的47.7亿美元，预测期内（2026-2034年）复合年增长率（CAGR）为8.25%。

北美引领全球介入性肿瘤学市场，2025年占42.20%的市占率。这主要归功于其先进的医疗基础设施、较高的癌症发生率以及早期采用影像引导微创肿瘤治疗方法。

介入性肿瘤学是指利用影像导引的微创技术（例如消融术、栓塞术和放射疗法）对癌症进行诊断、治疗和安宁疗护。这些手术方式越来越受到青睐，优于传统的开放性手术，有住院时间短、併发症风险低、復健快等优势。

新冠疫情对市场的影响

由于封锁限制、癌症治疗延迟以及门诊就诊量减少，介入肿瘤学市场在新冠疫情期间经历了暂时性下滑。 2020年，许多择期肿瘤治疗被推迟，对手术量产生了负面影响。

然而，随着限制措施的放宽，2021年癌症诊断和治疗的就诊量显着增加，弥补了延期手术造成的损失。因此，市场正在重拾成长势头，预计在预测期内将稳定成长。

市场趋势

放射乳化技术的日益普及

介入性肿瘤学市场最显着的趋势之一是放射乳化技术的日益普及。 这种微创技术将放射性微球直接输送到肿瘤的供血血管中，在最大限度减少对周围组织损伤的同时，摧毁目标肿瘤。

放射乳化疗法最初是为治疗肝癌而开发的，目前正在探索将其用于治疗大肠直肠癌和神经内分泌肿瘤。北美放射学会于2022年6月发表的一项研究报告称，接受经动脉放射乳化疗法治疗转移性大肠直肠癌的患者平均存活期为15个月，这进一步支持了该疗法的临床应用。

市场成长驱动因素

全球癌症发生率上升

癌症发生率的上升是市场成长的主要驱动因素。根据世界卫生组织（WHO）统计，2020年全球约有2,000万例新增癌症病例和970万例癌症相关死亡病例。肝癌、肺癌、乳癌和肾癌等常见癌症持续推动对有效治疗方案的需求。

转向微创手术

由于微创手术 (MIS) 具有许多优势，包括减轻疼痛、缩短住院时间、加速復健以及降低併发症发生率，患者和医疗服务提供者越来越倾向于选择微创手术。研究表明，与开放性手术相比，接受微创手术的患者併发症更少，这推动了介入性肿瘤学技术的广泛应用。

市场限制因子

儘管市场成长潜力巨大，但介入性肿瘤学手术和设备的高昂成本仍然是市场面临的挑战。先进的影像系统、栓塞装置和消融技术都需要大量的资金投入。 此外，训练有素的介入性肿瘤科医生短缺，尤其是在发展中地区，限制了市场渗透率和患者获得先进治疗的机会。

市场区隔分析

依类型

预计2026年，放射治疗设备将占市场主导地位，市占率达49.48%，主要得益于癌症相关住院人数的增加。栓塞设备由于其精准性和有效性，预计将实现最高的复合年增长率。

依癌症类型

预计到2026年，肝癌细分市场将占最大的市场占有率，达到59.70%，这主要归功于栓塞和消融疗法的高普及率。

依最终使用者

预计到2026年，医院将占市场主导地位，市场占有率达67.34%，这主要得益于患者数量的增加和先进治疗基础设施的发展。

区域概览

  • 北美：市场规模在2025年达到9.9亿美元。预计到2026年，美国市场规模将达到10亿美元。
  • 欧洲：肺癌发生率上升和医疗基础设施改善推动了市场成长。
  • 亚太地区：由于中国、日本和印度的医疗基础设施改善以及医疗器材普及率提高，预计亚太地区的复合年增长率将最高。

主要公司

主要公司包括波士顿科学公司、西门子医疗、泰尔茂株式会社、美瑞医疗系统、BD和AngioDynamics。产品创新和获得监管部门批准仍然是关键的成长策略。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家癌症盛行率（2025 年）
  • 主要产业趋势：併购、业务合作
  • 概述：介入性肿瘤学的技术进步
  • 新冠疫情对市场的影响

第五章 全球介入性肿瘤学市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 放射治疗设备
    • 消融设备
      • 微波消融
      • 射频消融
      • 冷冻消融
      • 其他
    • 栓塞设备
      • 微导管
      • 指南年份
  • 市场分析、洞察与预测：依癌症类型划分
    • 肺癌
    • 肝癌
    • 肾癌
    • 其他
  • 市场分析、洞察与预测：依最终用户划分
    • 医院
    • 专科诊所
    • 其他
  • 市场分析，洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区 (ROW)

第六章：北美介入性肿瘤市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲介入性肿瘤市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲国家

第八章 亚太地区介入肿瘤市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 亚太其他地区

第九章：世界其他地区（ROW）介入肿瘤市场分析：洞察与预测（2021-2034）

第十章：竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • Boston Scientific Corporation
    • Merit Medical Systems
    • Terumo Corporation
    • Siemens Healthcare GmbH
    • BD
    • AngioDynamics
    • Hologic, Inc.
    • Teleflex Incorporated
Product Code: FBI101986

Growth Factors of interventional oncology Market

The global interventional oncology market is experiencing consistent growth due to the rising global cancer burden and increasing preference for minimally invasive cancer treatment procedures. In 2025, the global interventional oncology market was valued at USD 2.34 billion. The market is projected to grow from USD 2.53 billion in 2026 and reach USD 4.77 billion by 2034, registering a CAGR of 8.25% during the forecast period (2026-2034).

North America dominated the global interventional oncology market with a 42.20% market share in 2025, driven by advanced healthcare infrastructure, high cancer prevalence, and early adoption of image-guided minimally invasive oncology procedures.

Interventional oncology involves the diagnosis, treatment, and palliation of cancer using image-guided, minimally invasive techniques, including ablation, embolization, and radiation-based therapies. These procedures offer benefits such as reduced hospital stays, lower complication risks, and faster recovery, making them increasingly preferred over conventional open surgeries.

Impact of COVID-19 on the Market

The interventional oncology market witnessed a temporary decline during the COVID-19 pandemic due to lockdown restrictions, postponed cancer treatments, and reduced hospital visits. Many elective oncology procedures were delayed in 2020, negatively impacting procedural volumes.

However, with the lifting of restrictions, hospital visits for cancer diagnosis and treatment increased significantly in 2021, compensating for the delayed procedures. As a result, the market regained momentum and is expected to witness steady growth throughout the forecast period.

Market Trends

Growing Adoption of Radioembolization

One of the most prominent trends in the interventional oncology market is the increasing adoption of radioembolization. This minimally invasive technique delivers radioactive microspheres directly to tumor-feeding blood vessels, offering targeted tumor destruction with minimal damage to surrounding tissues.

Originally developed for liver cancer, radioembolization is now being explored for colorectal cancer and neuroendocrine tumors. In June 2022, research published by the Radiological Society of North America reported a 15-month survival rate in patients undergoing transarterial radioembolization for metastatic colorectal cancer, further supporting its clinical adoption.

Market Growth Drivers

Rising Global Cancer Prevalence

The increasing prevalence of cancer is a major driver of market growth. According to the World Health Organization (WHO), there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2020. Common cancers such as liver, lung, breast, and kidney cancers continue to drive demand for effective treatment solutions.

Shift Toward Minimally Invasive Procedures

Patients and healthcare providers are increasingly preferring minimally invasive surgical (MIS) procedures due to advantages such as reduced pain, shorter hospital stays, faster recovery, and lower complication rates. Studies have shown that patients undergoing MIS procedures experience fewer complications compared to open surgery, encouraging wider adoption of interventional oncology techniques.

Market Restraints

Despite strong growth potential, the market faces challenges related to the high cost of interventional oncology procedures and devices. Advanced imaging systems, embolization devices, and ablation technologies require significant capital investment. Additionally, the shortage of trained interventional oncologists, especially in developing regions, limits market penetration and patient access to advanced treatments.

Segmentation Analysis

By Type

Radiation therapy devices dominated the market with a 49.48% share in 2026, supported by rising cancer-related hospitalizations. Embolization devices are expected to register the highest CAGR due to their precision and effectiveness.

By Cancer Type

The liver cancer segment held the largest market share at 59.70% in 2026, driven by high adoption of embolization and ablation therapies.

By End User

Hospitals dominated the market with a 67.34% share in 2026, owing to increasing patient admissions and availability of advanced treatment infrastructure.

Regional Insights

  • North America: Market value reached USD 0.99 billion in 2025; the U.S. market is projected to reach USD 1.0 billion by 2026.
  • Europe: Growth supported by rising lung cancer prevalence and improved healthcare infrastructure.
  • Asia Pacific: Expected to grow at the highest CAGR due to infrastructure development and increasing device launches in China, Japan, and India.

Key Industry Players

Major companies include Boston Scientific Corporation, Siemens Healthineers, Terumo Corporation, Merit Medical Systems, BD, and AngioDynamics. Product innovation and regulatory approvals remain key growth strategies.

Conclusion

The global interventional oncology market is set to witness robust growth, expanding from USD 2.34 billion in 2025 to USD 4.77 billion by 2034. Rising cancer prevalence, growing preference for minimally invasive procedures, and continuous technological advancements are driving market expansion. Although high treatment costs and limited availability of skilled professionals pose challenges, increasing investments in healthcare infrastructure and innovation are expected to support sustained market growth during the forecast period.

Segmentation By Type

  • Radiation Therapy Devices
  • Ablation Devices
    • Microwave ablation
    • Radiofrequency ablation
    • Cryoablation
    • Others
  • Embolization Devices
    • Microcatheters
    • Guidewires

By Cancer Type

  • Lung Cancer
  • Liver Cancer
  • Kidney Cancer
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (By Type, Cancer Type, End-user, and Country)
    • U.S. (By Cancer Type)
    • Canada (By Cancer Type)
  • Europe (By Type, Cancer Type, End-user, and Country/Sub-region)
    • U.K. (By Cancer Type)
    • Germany (By Cancer Type)
    • France (By Cancer Type)
    • Spain (By Cancer Type)
    • Italy (By Cancer Type)
    • Rest of Europe (By Cancer Type)
  • Asia Pacific (By Type, Cancer Type, End-user, and Country/Sub-region)
    • Japan (By Cancer Type)
    • China (By Cancer Type)
    • India (By Cancer Type)
    • Australia (By Cancer Type)
    • Rest of Asia Pacific (By Cancer Type)
  • Rest of the World (By Type, Cancer Type, and End-user)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer Diseases, By Key Countries, 2025
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships)
  • 4.3. Overview: Technological Advancements in Interventional Oncology
  • 4.4. Impact of COVID-19 on the Market

5. Global Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Radiation Therapy Devices
    • 5.1.2. Ablation Devices
      • 5.1.2.1. Microwave Ablation
      • 5.1.2.2. Radiofrequency Ablation
      • 5.1.2.3. Cryoablation
      • 5.1.2.4. Others
    • 5.1.3. Embolization Devices
      • 5.1.3.1. Microcatheters
      • 5.1.3.2. Guidewires
  • 5.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.2.1. Lung Cancer
    • 5.2.2. Liver Cancer
    • 5.2.3. Kidney Cancer
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals
    • 5.3.2. Specialty Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Radiation Therapy Devices
    • 6.1.2. Ablation Devices
      • 6.1.2.1. Microwave Ablation
      • 6.1.2.2. Radiofrequency Ablation
      • 6.1.2.3. Cryoablation
      • 6.1.2.4. Others
    • 6.1.3. Embolization Devices
      • 6.1.3.1. Microcatheters
      • 6.1.3.2. Guidewires
  • 6.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.2.1. Lung Cancer
    • 6.2.2. Liver Cancer
    • 6.2.3. Kidney Cancer
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals
    • 6.3.2. Specialty Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Cancer Type
    • 6.4.2. Canada
      • 6.4.2.1. By Cancer Type

7. Europe Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Radiation Therapy Devices
    • 7.1.2. Ablation Devices
      • 7.1.2.1. Microwave Ablation
      • 7.1.2.2. Radiofrequency Ablation
      • 7.1.2.3. Cryoablation
      • 7.1.2.4. Others
    • 7.1.3. Embolization Devices
      • 7.1.3.1. Microcatheters
      • 7.1.3.2. Guidewires
  • 7.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.2.1. Lung Cancer
    • 7.2.2. Liver Cancer
    • 7.2.3. Kidney Cancer
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Cancer Type
    • 7.4.2. Germany
      • 7.4.2.1. By Cancer Type
    • 7.4.3. France
      • 7.4.3.1. By Cancer Type
    • 7.4.4. Spain
      • 7.4.4.1. By Cancer Type
    • 7.4.5. Italy
      • 7.4.5.1. By Cancer Type
    • 7.4.6. Rest of Europe
      • 7.4.6.1. By Cancer Type

8. Asia Pacific Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Radiation Therapy Devices
    • 8.1.2. Ablation Devices
      • 8.1.2.1. Microwave Ablation
      • 8.1.2.2. Radiofrequency Ablation
      • 8.1.2.3. Cryoablation
      • 8.1.2.4. Others
    • 8.1.3. Embolization Devices
      • 8.1.3.1. Microcatheters
      • 8.1.3.2. Guidewires
  • 8.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.2.1. Lung Cancer
    • 8.2.2. Liver Cancer
    • 8.2.3. Kidney Cancer
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals
    • 8.3.2. Specialty Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Cancer Type
    • 8.4.2. China
      • 8.4.2.1. By Cancer Type
    • 8.4.3. India
      • 8.4.3.1. By Cancer Type
    • 8.4.4. Australia
      • 8.4.4.1. By Cancer Type
    • 8.4.5. Rest of Asia Pacific
      • 8.4.5.1. By Cancer Type

9. Rest of the World Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Radiation Therapy Devices
    • 9.1.2. Ablation Devices
      • 9.1.2.1. Microwave Ablation
      • 9.1.2.2. Radiofrequency Ablation
      • 9.1.2.3. Cryoablation
      • 9.1.2.4. Others
    • 9.1.3. Embolization Devices
      • 9.1.3.1. Microcatheters
      • 9.1.3.2. Guidewires
  • 9.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.2.1. Lung Cancer
    • 9.2.2. Liver Cancer
    • 9.2.3. Kidney Cancer
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Boston Scientific Corporation
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Merit Medical Systems
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Terumo Corporation
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Siemens Healthcare GmbH
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. BD
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. AngioDynamics
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Hologic, Inc.
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Teleflex Incorporated
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 3: Global Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 4: Global Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 5: Global Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 6: Global Interventional Oncology Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 9: North America Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 10: North America Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 11: North America Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 12: North America Interventional Oncology Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: U.S. Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 14: Canada Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 15: Europe Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 16: Europe Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 17: Europe Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 18: Europe Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 19: Europe Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 20: Europe Interventional Oncology Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: U.K. Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 22: Germany Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 23: France Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 24: Spain Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 25: Italy Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 26: Rest of the Europe Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 27: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 28: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 29: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 30: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 31: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 32: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 33: China Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 34: Japan Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 35: India Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 36: Australia Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 37: Rest of the Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 38: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 39: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 40: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 41: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 42: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034

List of Figures

  • Figure 1: Global Interventional Oncology Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Interventional Oncology Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Interventional Oncology Market Value Share (%), By Cancer Type, 2025 & 2034
  • Figure 4: Global Interventional Oncology Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Interventional Oncology Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Interventional Oncology Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Interventional Oncology Market Value Share (%), by Type, 2025
  • Figure 8: North America Interventional Oncology Market Value (USD billion), By Cancer Type, 2025 & 2034
  • Figure 9: North America Interventional Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 10: North America Interventional Oncology Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 11: North America Interventional Oncology Market Value Share (%), by End-user, 2025
  • Figure 12: North America Interventional Oncology Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Interventional Oncology Market Value Share (%), By Country, 2025
  • Figure 14: Europe Interventional Oncology Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Interventional Oncology Market Value Share (%), by Type, 2025
  • Figure 16: Europe Interventional Oncology Market Value (USD billion), By Cancer Type, 2025 & 2034
  • Figure 17: Europe Interventional Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 18: Europe Interventional Oncology Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 19: Europe Interventional Oncology Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Interventional Oncology Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Interventional Oncology Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Interventional Oncology Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Interventional Oncology Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Interventional Oncology Market Value (USD billion), By Cancer Type, 2025 & 2034
  • Figure 25: Asia Pacific Interventional Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 26: Asia Pacific Interventional Oncology Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Interventional Oncology Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Interventional Oncology Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Interventional Oncology Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World Interventional Oncology Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Rest of the World Interventional Oncology Market Value Share (%), by Type, 2025
  • Figure 32: Rest of the World Interventional Oncology Market Value (USD billion), By Cancer Type, 2025 & 2034
  • Figure 33: Rest of the World Interventional Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 34: Rest of the World Interventional Oncology Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 35: Rest of the World Interventional Oncology Market Value Share (%), by End-user, 2025
  • Figure 36: Global Interventional Oncology Market Share (%), By Company, 2025